Intarcia Therapeutics, Inc.

91 articles with Intarcia Therapeutics, Inc.

• Numab Announces Entry into a License Agreement With Intarcia for Anti-Inflammatory ND016

  3/5/2019

  Numab Therapeutics AG today announced that Intarcia Therapeutics Inc. has executed its option to in-license ND016, being developed for the treatment of autoimmune disorders.

• Intarcia Provides 2019 Corporate Update

  12/18/2018

   Intarcia Therapeutics Inc. today provided an update on the company's progress in 2018 and trajectory for advancement in 2019.

• 

  Bay State is Home to Four Biotech Unicorns

  8/17/2018

  When people hear the word “unicorn” they may think of the mythical horse with a polished horn protruding from its brow. But in the world of investing, the term unicorn refers to a startup company worth more than $1 billion.

• Intarcia Appoints Thane Wettig as Chief Marketing Officer and Metabolic Franchise Head

  7/3/2018

  Wettig Brings Strong Background in Diabetes and Metabolic Diseases from Leading Global Diabetes Company

• 

  Foresite Capital Launches New Venture Capital Fund Worth $668 Million

  5/3/2018

  Venture capital firm Foresite Capital, located in San Francisco, is launching a new fund, its fourth and largest, worth $668 million.
• 

  Digital Health Movement Continues to Grow, as Do Concerns Over Privacy

  5/2/2018

  Getting patients to adhere to long-term treatments can be difficult. There are a number of new therapies that will monitor whether or not patients are sticking to their regimen.
• 

  Is There a Biotech Bubble Brewing in Boston?

  3/21/2018

  Billions of dollars are being invested in Boston-based life science companies.
• 

  Boston's Intarcia Pink Slips 60 Employees, Terminates Two Late-Stage Trials

  2/5/2018

  A tipster told BioSpace that the layoffs were initially announced by Intarcia CEO Kurt Graves on Jan. 31.
• 

  Can 2018 Possibly Rival 2017's Biotechs Record Venture Capital Splurge?

  1/10/2018

  A look at whether big money and big deals will be in store for 2018.

• Manufacturing Issues Force The FDA To Reject Intarcia's Diabetic Drug Pump

  9/28/2017

• Intarcia Strengthens Board Of Directors For Next Stage Of Growth

  9/20/2017

• New Intarcia Study Evaluates Optimal Way To Switch From Daily Liraglutide Injections To ITCA 650 In Patients With Type 2 Diabetes

  9/15/2017

• Intarcia And Numab AG Reach Key Milestone With Selection Of Multi-Specific Development Candidate For Autoimmune Disease

  9/14/2017

• Fast-Growing Intarcia Awaits Crucial FDA Decision in New Boston HQ

  5/8/2017

• Intarcia Announces FDA Filing Acceptance Of New Drug Application (NDA) For ITCA 650 For The Treatment Of Type 2 Diabetes

  2/6/2017

• Intarcia And Calibr Announce Collaboration And In-Licensing Deal Aimed At Delivering A Next Generation Combination Product For Diabetes And Obesity

  1/9/2017

• Bill & Melinda Gates Foundation Sends $140M to Intarcia for HIV Version of Pump

  12/30/2016

• Intarcia Secures Second Close Of The Series EE Equity Financing For An Additional $206M

  12/29/2016

• Intarcia Submits New Drug Application (NDA) To FDA For U.S. Marketing Approval Of ITCA 650 In Type 2 Diabetes

  11/21/2016

• Week In Review: China's Luxin Invests In $215 Million Funding For Intarcia's Long-Term Diabetes Device

  9/19/2016